Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction
Primary Purpose
Cholangiocarcinoma, Gallbladder Carcinoma, Hepatocellular Carcinoma
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
biliary stent
Sponsored by
About this trial
This is an interventional treatment trial for Cholangiocarcinoma
Eligibility Criteria
Inclusion Criteria:
- Malignant hilar biliary obstruction;
- Unresectable cases
Exclusion Criteria:
- Bismuth I patients;
- inability to obtain informed consent;
- Eastern Cooperative Oncology Group performance status of 4;
- severe dysfunction in other organs.
Sites / Locations
- Xuzhou Central Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Unilateral stent
Bilateral stents
Arm Description
Patients undergo placement of unilateral biliary stent on day 1.
Patients undergo placement of bilateral biliary stents on day 1.
Outcomes
Primary Outcome Measures
Stent patency (Stent dysfunction is suspected when the patient experiences recurrence of jaundice)
Stent dysfunction is suspected when the patient experiences recurrence of jaundice.
Secondary Outcome Measures
Overall survival
From the date of randomization until the date of first documented death from any cause.
Stent dysfunction free-patient survival
From the date of randomization until the date of first documented stent dysfunction or the date of death from any cause, whichever came first.
Full Information
NCT ID
NCT02649712
First Posted
January 6, 2016
Last Updated
November 18, 2018
Sponsor
Xuzhou Central Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02649712
Brief Title
Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction
Official Title
Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
January 20, 2016 (Actual)
Primary Completion Date
October 31, 2018 (Actual)
Study Completion Date
October 31, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Xuzhou Central Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with malignant hilar biliary obstruction who are treated by unilateral or bilateral stenting.
Detailed Description
Malignant hilar biliary obstruction is a common clinical manifestation and it can be caused by cholangiocarcinoma, gallbladder carcinoma, liver cancer, or other metastatic carcinoma. Most patients with malignant hilar biliary obstruction are unresectable at diagnosis. Biliary stenting has been widely used in palliative treatment of malignant hilar biliary obstruction.
Hilar biliary obstruction usually involves the bifurcation of the biliary tract. Some researchers recommended unilateral stenting for malignant hilar biliary obstruction because drainage of 25% of entire liver can achieve the clinical success of biliary drainage. However, some researchers recommended bilateral stenting for malignant hilar biliary obstruction because some researches demonstrated that bilateral stenting can achieve a longer stent patency.In addition, there was no significant difference in post stenting survival between patients who were treated by unilateral or bilateral stenting. Therefore, it remains under debate whether unilateral or bilateral stenting is better in the treatment of malignant hilar biliary obstruction.
The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with malignant hilar biliary obstruction who are treated by unilateral or bilateral stenting.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholangiocarcinoma, Gallbladder Carcinoma, Hepatocellular Carcinoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
72 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Unilateral stent
Arm Type
Active Comparator
Arm Description
Patients undergo placement of unilateral biliary stent on day 1.
Arm Title
Bilateral stents
Arm Type
Active Comparator
Arm Description
Patients undergo placement of bilateral biliary stents on day 1.
Intervention Type
Device
Intervention Name(s)
biliary stent
Intervention Description
Self-expandable biliary nitinol alloys stent
Primary Outcome Measure Information:
Title
Stent patency (Stent dysfunction is suspected when the patient experiences recurrence of jaundice)
Description
Stent dysfunction is suspected when the patient experiences recurrence of jaundice.
Time Frame
From the date of randomization until the date of first documented stent dysfunction, assessed up to 10 months
Secondary Outcome Measure Information:
Title
Overall survival
Description
From the date of randomization until the date of first documented death from any cause.
Time Frame
From the date of randomization until the date of first documented death from any cause, assessed up to 12 months
Title
Stent dysfunction free-patient survival
Description
From the date of randomization until the date of first documented stent dysfunction or the date of death from any cause, whichever came first.
Time Frame
From the date of randomization until the date of first documented stent dysfunction or the date of death from any cause, whichever came first, assessed up to 10 months.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Malignant hilar biliary obstruction;
Unresectable cases
Exclusion Criteria:
Bismuth I patients;
inability to obtain informed consent;
Eastern Cooperative Oncology Group performance status of 4;
severe dysfunction in other organs.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chi Cao, MD
Organizational Affiliation
Xuzhou Central Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xuzhou Central Hospital
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221009
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
There is not a plan to make individual participant data available.
Citations:
PubMed Identifier
21198916
Citation
Iwano H, Ryozawa S, Ishigaki N, Taba K, Senyo M, Yoshida K, Sakaida I. Unilateral versus bilateral drainage using self-expandable metallic stent for unresectable hilar biliary obstruction. Dig Endosc. 2011 Jan;23(1):43-8. doi: 10.1111/j.1443-1661.2010.01036.x. Epub 2010 Nov 30.
Results Reference
background
PubMed Identifier
23617655
Citation
Yasuda I, Mukai T, Moriwaki H. Unilateral versus bilateral endoscopic biliary stenting for malignant hilar biliary strictures. Dig Endosc. 2013 May;25 Suppl 2:81-5. doi: 10.1111/den.12060.
Results Reference
background
PubMed Identifier
22873816
Citation
Liberato MJ, Canena JM. Endoscopic stenting for hilar cholangiocarcinoma: efficacy of unilateral and bilateral placement of plastic and metal stents in a retrospective review of 480 patients. BMC Gastroenterol. 2012 Aug 9;12:103. doi: 10.1186/1471-230X-12-103.
Results Reference
background
PubMed Identifier
21940566
Citation
Gwon DI, Ko GY, Sung KB, Yoon HK, Shin JH, Hyoung Kim J, Kim J, Oh JY. Percutaneous biliary metallic stent placement in patients with unilobar portal vein occlusion caused by advanced hilar malignancy: outcome of unilateral versus bilateral stenting. AJR Am J Roentgenol. 2011 Oct;197(4):795-801. doi: 10.2214/AJR.11.6424.
Results Reference
background
PubMed Identifier
22415652
Citation
Mukai T, Yasuda I, Nakashima M, Doi S, Iwashita T, Iwata K, Kato T, Tomita E, Moriwaki H. Metallic stents are more efficacious than plastic stents in unresectable malignant hilar biliary strictures: a randomized controlled trial. J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):214-22. doi: 10.1007/s00534-012-0508-8.
Results Reference
background
PubMed Identifier
22484591
Citation
Bulajic M, Panic N, Radunovic M, Scepanovic R, Perunovic R, Stevanovic P, Ille T, Zilli M, Bulajic M. Clinical outcome in patients with hilar malignant strictures type II Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage. Hepatobiliary Pancreat Dis Int. 2012 Apr;11(2):209-14. doi: 10.1016/s1499-3872(12)60150-7.
Results Reference
background
PubMed Identifier
14605106
Citation
Inal M, Akgul E, Aksungur E, Seydaoglu G. Percutaneous placement of biliary metallic stents in patients with malignant hilar obstruction: unilobar versus bilobar drainage. J Vasc Interv Radiol. 2003 Nov;14(11):1409-16. doi: 10.1097/01.rvi.0000096762.74047.a6.
Results Reference
background
PubMed Identifier
19220678
Citation
Naitoh I, Ohara H, Nakazawa T, Ando T, Hayashi K, Okumura F, Okayama Y, Sano H, Kitajima Y, Hirai M, Ban T, Miyabe K, Ueno K, Yamashita H, Joh T. Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction. J Gastroenterol Hepatol. 2009 Apr;24(4):552-7. doi: 10.1111/j.1440-1746.2008.05750.x. Epub 2009 Feb 12.
Results Reference
background
PubMed Identifier
25880978
Citation
Li M, Wu W, Yin Z, Han G. [Unilateral versus bilateral biliary drainage for malignant hilar obstruction: a systematic review and meta-analysis]. Zhonghua Gan Zang Bing Za Zhi. 2015 Feb;23(2):118-23. doi: 10.3760/cma.j.issn.1007-3418.2015.02.009. Chinese.
Results Reference
background
PubMed Identifier
30968181
Citation
Fu YF, Zhou WJ, Shi YB, Cao W, Cao C. Percutaneous stenting for malignant hilar biliary obstruction: a randomized controlled trial of unilateral versus bilateral stenting. Abdom Radiol (NY). 2019 Aug;44(8):2900-2908. doi: 10.1007/s00261-019-02010-6.
Results Reference
derived
Learn more about this trial
Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction
We'll reach out to this number within 24 hrs